Beam Therapeutics (NASDAQ:BEAM) Price Target Raised to $68.00 at Citigroup

Beam Therapeutics (NASDAQ:BEAM) had its price target increased by Citigroup from $64.00 to $68.00 in a research report sent to investors on Thursday,Benzinga reports. They currently have a buy rating on the stock.

BEAM has been the topic of a number of other research reports. UBS Group began coverage on Beam Therapeutics in a research report on Wednesday, January 7th. They issued a “neutral” rating and a $28.00 target price on the stock. Wedbush increased their price target on Beam Therapeutics from $57.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Beam Therapeutics in a research report on Wednesday, January 21st. Sanford C. Bernstein boosted their price objective on shares of Beam Therapeutics from $37.00 to $41.00 and gave the company an “outperform” rating in a report on Tuesday, January 20th. Finally, Tudor Pickering set a $41.00 target price on shares of Beam Therapeutics in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $48.87.

Beam Therapeutics Price Performance

Beam Therapeutics stock opened at $23.62 on Thursday. The firm has a 50 day simple moving average of $27.63 and a 200-day simple moving average of $26.26. The stock has a market cap of $2.41 billion, a price-to-earnings ratio of -23.39 and a beta of 2.12. Beam Therapeutics has a 1-year low of $13.52 and a 1-year high of $36.44.

Beam Therapeutics (NASDAQ:BEAM) last released its quarterly earnings results on Tuesday, February 24th. The company reported $2.33 EPS for the quarter, beating the consensus estimate of ($1.13) by $3.46. Beam Therapeutics had a negative net margin of 57.24% and a negative return on equity of 30.65%. The firm had revenue of $114.11 million for the quarter, compared to analyst estimates of $13.22 million. During the same quarter in the previous year, the company earned ($1.09) EPS. The business’s revenue for the quarter was up 280.3% compared to the same quarter last year. Equities analysts expect that Beam Therapeutics will post -4.57 earnings per share for the current fiscal year.

Insider Buying and Selling at Beam Therapeutics

In other news, insider Christine Bellon sold 1,371 shares of Beam Therapeutics stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $34.00, for a total value of $46,614.00. Following the completion of the sale, the insider directly owned 95,667 shares of the company’s stock, valued at approximately $3,252,678. The trade was a 1.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 3.50% of the company’s stock.

Hedge Funds Weigh In On Beam Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. ARK Investment Management LLC increased its stake in Beam Therapeutics by 24.8% during the third quarter. ARK Investment Management LLC now owns 11,038,834 shares of the company’s stock worth $267,913,000 after purchasing an additional 2,190,993 shares during the period. Contrarius Group Holdings Ltd purchased a new position in shares of Beam Therapeutics in the third quarter valued at approximately $37,212,000. MWG Caph Ltd purchased a new position in shares of Beam Therapeutics in the fourth quarter valued at approximately $35,119,000. State Street Corp grew its holdings in shares of Beam Therapeutics by 30.4% in the fourth quarter. State Street Corp now owns 5,228,529 shares of the company’s stock valued at $144,935,000 after purchasing an additional 1,219,871 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Beam Therapeutics by 237.5% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,665,385 shares of the company’s stock valued at $40,419,000 after purchasing an additional 1,171,977 shares in the last quarter. 99.68% of the stock is currently owned by hedge funds and other institutional investors.

More Beam Therapeutics News

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: Updated Phase 1/2 results show BEAM‑302 (60 mg) produced mean steady‑state total AAT of 16.1 µM (above the 11 µM protective threshold), corrected M‑AAT comprised ~94% of circulating AAT and mutant Z‑AAT fell ~84% — data the company says support a one‑time, disease‑modifying treatment and the move to pivotal development. GlobeNewswire Release
• Positive Sentiment: Beam says it will pursue an accelerated approval pathway per FDA feedback and expects to start a global pivotal cohort in H2 2026 — a faster regulatory path would materially de‑risk timing for a potential approval and commercial milestone realization. BioSpace Article
• Positive Sentiment: Sell‑side momentum: Citigroup raised its price target to $68 with a Buy rating (boosting upside expectations versus current levels), reflecting increased analyst conviction after the BEAM‑302 update. Benzinga (Citigroup note)
• Neutral Sentiment: Beam hosted an investor webcast to review the data and reiterate the 60 mg dose selection and development plan; management set expectations for enrolling ~50 additional patients for a pivotal expansion. Benzinga Clinical Update
• Neutral Sentiment: Market and analyst coverage is mixed but active — multiple firms maintain bullish long‑term targets (median target elevated vs. current price) which supports analyst‑driven flows but also reflects valuation dispersion. Zacks Summary
• Negative Sentiment: Safety watch: while single‑dose cohorts showed tolerability up to 75 mg, the small multi‑dose cohort had ALT/AST elevations (one Grade 4 ALT, Grade 3 AST) after a second dose — a safety signal that could complicate multi‑dose strategies or raise regulator questions. BioPharmaDive Coverage
• Negative Sentiment: Recent insider selling and large institutional portfolio trimming noted in data summaries may damp investor sentiment despite the clinical news; and the stock still trades below its 50‑day and 200‑day moving averages, which can limit near‑term technical momentum. Quiver Quant Summary

About Beam Therapeutics

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.